Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report.

BMC Res Notes · 2017 · PMC5526247 · PMID 28743309

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes pmc-license-ref CC BY issue-copyright-statement © The Author(s) 2017 Background BRAF inhibitors have revolutionized the treatment of metastatic melanoma in patients presenting a BRAF V600 mutation in their tumor by showing highly significant clinical objective responses [ 1 – 5 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.